A detailed history of Point72 Hong Kong LTD transactions in Novo Cure LTD stock. As of the latest transaction made, Point72 Hong Kong LTD holds 7,684 shares of NVCR stock, worth $188,411. This represents 0.01% of its overall portfolio holdings.

Number of Shares
7,684
Previous 18,624 58.74%
Holding current value
$188,411
Previous $319,000 62.38%
% of portfolio
0.01%
Previous 0.02%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$15.61 - $23.34 $170,773 - $255,339
-10,940 Reduced 58.74%
7,684 $120,000
Q2 2024

Aug 14, 2024

BUY
$11.83 - $24.05 $205,664 - $418,109
17,385 Added 1403.15%
18,624 $319,000
Q1 2024

May 15, 2024

BUY
$12.42 - $17.29 $15,388 - $21,422
1,239 New
1,239 $19,000
Q1 2022

May 16, 2022

SELL
$60.15 - $84.52 $290,223 - $407,809
-4,825 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$75.08 - $121.99 $277,720 - $451,241
3,699 Added 328.51%
4,825 $362,000
Q3 2021

Nov 15, 2021

SELL
$116.17 - $194.55 $370,698 - $620,809
-3,191 Reduced 73.92%
1,126 $131,000
Q2 2021

Aug 16, 2021

BUY
$130.4 - $225.58 $562,936 - $973,828
4,317 New
4,317 $958,000
Q4 2020

Feb 16, 2021

SELL
$112.16 - $174.14 $347,583 - $539,659
-3,099 Closed
0 $0
Q3 2020

Nov 16, 2020

SELL
$58.05 - $111.31 $23,568 - $45,191
-406 Reduced 11.58%
3,099 $345,000
Q2 2020

Aug 14, 2020

BUY
$57.2 - $74.41 $200,486 - $260,807
3,505 New
3,505 $208,000
Q4 2019

Feb 14, 2020

SELL
$68.3 - $93.8 $956 - $1,313
-14 Closed
0 $0
Q3 2019

Nov 14, 2019

SELL
$61.86 - $97.8 $30,249 - $47,824
-489 Reduced 97.22%
14 $1,000
Q2 2019

Aug 14, 2019

BUY
$42.22 - $63.23 $19,758 - $29,591
468 Added 1337.14%
503 $32,000
Q1 2019

May 15, 2019

BUY
$31.96 - $56.12 $1,118 - $1,964
35 New
35 $2,000
Q4 2018

Feb 14, 2019

SELL
$28.72 - $52.63 $16,169 - $29,630
-563 Closed
0 $0
Q3 2018

Nov 14, 2018

BUY
$32.0 - $52.4 $18,016 - $29,501
563 New
563 $30,000

Others Institutions Holding NVCR

About NovoCure Ltd


  • Ticker NVCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Instruments & Supplies
  • Shares Outstandng 104,950,000
  • Market Cap $2.57B
  • Description
  • NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...
More about NVCR
Track This Portfolio

Track Point72 Hong Kong LTD Portfolio

Follow Point72 Hong Kong LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Hong Kong LTD, based on Form 13F filings with the SEC.

News

Stay updated on Point72 Hong Kong LTD with notifications on news.